Tools for Practice Outils pour la pratique


#6 PPIs and clopidogrel: Never the twain shall meet?


CLINICAL QUESTION
QUESTION CLINIQUE
Do proton pump inhibitors (PPIs) interact with clopidogrel to reduce its cardiovascular (CV) benefit?


BOTTOM LINE
RÉSULTAT FINAL
Studies are inconsistent about the impact of PPIs on clopidogrel effectiveness, though most higher-quality studies show no interaction. The association with CV risk seen with PPI use is likely due to underlying comorbidities rather than a true drug interaction.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
A systematic review1 of 33 studies encompasses the best-available evidence. Highlights: 
  • ~50% of retrospective observational studies, and ~25% of prospective observational studies found a significant association of increased CV risk with PPI + clopidogrel versus clopidogrel alone. 
    • Retrospective studies generally had higher risk of bias. 
  • One randomized controlled trial (RCT)2 of 3,761 patients receiving clopidogrel and ASA followed for a median of 3.5 months: 
    • No difference in CV events, omeprazole 4.9% versus placebo 5.7%. 
    • Limitations: Unplanned early termination, underpowered for CV comparisons. 
  • Non-randomized subgroup analyses of landmark antiplatelet trials.3,4 
    • PPI did not increase CV risk with either clopidogrel or prasugrel. 
    • PPI increased CV risk with both clopidogrel (HR 1.20) and ticagrelor (HR 1.24). 
      • Note: Ticagrelor does not require enzymatic activation and should therefore not be affected by the postulated PPI drug interaction mechanism. 
Studies that included patients not receiving clopidogrel found that PPI use was associated with increased CV risk (regardless of clopidogrel use).5-9  Context: 
  • PPIs have inconsistent effects on surrogate markers of clopidogrel efficacy.1 
  • American guidelines12 (though based on outdated evidence) reasonably recommend careful assessment of the indication for PPIs, as they are frequently prescribed without a clear indication.13 
  • There is no consistent difference in CV risk association between PPIs, including pantoprazole.14 
Reviewed: July 13, 2016 by ricky


Latest Tools for Practice
Derniers outils pour la pratique

#359 Topical corticosteroids for atopic dermatitis - More than skin deep

What are the benefits/harms of topical corticosteroids for atopic dermatitis in adults/children?
Read Lire 0.25 credits available Crédits disponibles

#358: Any berry good solutions to preventing UTIs: Cranberries?

Do cranberry products prevent recurrent urinary tract infections (UTIs)?
Read Lire 0.25 credits available Crédits disponibles

#357: Overcoming Resistance: Antipsychotics for difficult to treat depression

In patients with treatment-resistant depression, is adding an atypical antipsychotic to current therapy safe and effective?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • G. Michael Allan MD CCFP
  • Michael R Kolber MD CCFP MSc

1. Jaspers Focks J, Brouwer MA, van Oijen MGH, et al. Heart. 2013; 99:520-7.

2. Bhatt DL, Cryer BL, Contant CF, et al. N Engl J Med. 2010; 363:1909-17.

3. O’Donoghue ML, Braunwald E, Antmann EM, et al. Lancet. 2009; 374:989-97.

4. Goodman SG, Clare R, Pieper KS, et al. Circulation. 2012; 125:978-86.

5. Dunn SP, Macaulay TE, Brennan DM, et al. Circulation. 2008; 118:S815.

6. Charlot M, Ahlehoff O, Norgaard ML, et al. Ann Intern Med. 2010; 153:378-86.

7. Valkhoff VE, ‘t Jong GW, van Soest EM, et al. Aliment Pharmacol Ther. 2011; 33:77-88.

8. Charlot M, Grove EL, Hansen PR. BMJ. 2011; 342:d2690.

9. Schmidt M, Johansen MB, Robertson DJ, et al. Aliment Pharmacol Ther. 2012; 35:165-74.

10. Juurlink DN, Gomes T, Ko DT, et al. CMAJ. 2009; 180:713-8.

11. Ho PM, Maddox Tm, Wang Li, et al. JAMA. 2009; 301:937-44.

12. Abraham NS, Hlatky MA, Antman EM, et al. Am J Gastroenterol. 2010; 105:2533-49.

13. Forgacs I, Loganayagam A. BMJ. 2008; 336:2-3.

14. Kwok CS, Jeevanantham, Dawn B, et al. Int J Cardiol. 2012; [Epub].

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.